Tango Therapeutics Q3 2021 net loss $19.6M; cash $503.8M funds into H2 2024

Tango Therapeutics, Inc.

2022-Q3 EPS reported -$0.68 revenue$31,326,000

Net loss of $19.6M ($0.28/share) vs $26.8M ($0.76) in Q3 2020; loss narrowed on revenue change.
Cash, equivalents and marketable securities $503.8M; management expects to fund operations into H2 2024.
Collaboration revenue was $6.8M vs negative $11.3M a year ago, due to Gilead amendment charge in Q3 2020.
TNG908 IND on track for Q4 2021; Phase 1/2 trial initiation expected in H1 2022.
Closed business combination with BCTG Acquisition Corp. and PIPE, yielding gross proceeds of $342M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.